SCHEMBL3135319

SCHEMBL3135319

COc1cc(OC)c2c(=O)c(O)c(-c3ccc(OC)c(OC)c3)oc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 1.00
CYP3A4 P08684 5/20 1.00
MAPT P10636 4/20 1.00
LMNA P02545 3/20 1.00
CASP1 P29466 3/20 1.00
CASP7 P55210 3/20 1.00
TP53 P04637 2/20 1.00
ABCG2 Q9UNQ0 5/20 0.81
MEN1 O00255 5/20 0.76
KMT2A Q03164 5/20 0.76
ABCB1 P08183 3/20 0.76
ALDH1A1 P00352 3/20 0.76
ABCC1 P33527 2/20 0.76
TDP1 Q9NUW8 2/20 0.76
MAPK1 P28482 1/20 0.76
XDH P47989 2/20 0.72
DPP4 P27487 1/20 0.72
HSD17B10 Q99714 2/20 0.65
IPMK Q8NFU5 2/20 0.65
IP6K2 Q9UHH9 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31412250 1.00 KDM4E (1.00) KDM4ECYP3A4MAPTLMNACASP1
SCHEMBL1250547 0.91 XDH (0.86) KDM4ECYP3A4MAPTLMNACASP1
SCHEMBL2629300 0.90 ABCG2 (1.00) KDM4ECYP3A4MAPTLMNACASP1
SCHEMBL26936149 0.89 KDM4E (0.82) KDM4ECYP3A4MAPTLMNACASP1
Pentamethylquercetin SCHEMBL16292202 0.88 KDM4E (0.77) KDM4ECYP3A4MAPTLMNACASP1
SCHEMBL748580 0.88 ABCG2 (0.86) KDM4ECYP3A4MAPTLMNACASP1
SCHEMBL4147950 0.87 ABCG2 (0.81) KDM4ECYP3A4MAPTLMNACASP1
SCHEMBL2629309 0.86 ABCG2 (0.84) KDM4ECYP3A4MAPTLMNACASP1
SCHEMBL14011591 0.86 ABCG2 (0.77) KDM4ECYP3A4MAPTLMNACASP1
SCHEMBL38650680 0.86 ABCG2 (0.83) KDM4ECYP3A4MAPTLMNACASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683095-B2 Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2010-03-23 US claimed
WO-2006132879-A2 SOFT GEL CAPSULES CONTAINING POLYMETHOXYLATED FLAVONES AND PALM OIL TOCOTRIENOLS SOFT GEL TECHNOLOGIES, INC. (US) 2006-12-14 WO claimed
US-6987125-B1 Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2006-01-17 US claimed
US-20060003947-A1 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols THE CIT GROUP/CREDIT FINANCE, INC. 2006-01-05 US claimed
US-20050249803-A1 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols SOFT GEL TECHNOLOGIES, INC. 2005-11-10 US claimed
EP-1278417-A1 COMPOSITIONS AND METHODS OF TREATING, REDUCING, AND PREVENTING CARDIOVASCULAR DISEASES AND DISORDERS WITH POLYMETHOXYFLAVONES KGK Synergie (CA) 2003-01-29 EP claimed
WO-2001070029-A1 COMPOSITIONS AND METHODS OF TREATING, REDUCING, AND PREVENTING CARDIOVASCULAR DISEASES AND DISORDERS WITH POLYMETHOXYFLAVONES KGK SYNERGIE (CA) 2001-09-27 WO claimed
US-20250011722-A1 HEPATIC ORGANOIDS KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) 2025-01-09 US disclosed
WO-2023085931-A1 HEPATIC ORGANOIDS KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) 2023-05-19 WO disclosed
CN-110818553-B Anti-inflammatory compound of desmodium parvifolium and preparation method thereof 青海师范大学 2022-06-14 CN disclosed
US-20220125766-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAGGIES PEARL LLC (US) 2022-04-28 US disclosed
US-20220125766-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAGGIES PEARL LLC (US) 2022-04-28 US disclosed
US-11160794-B2 Methods for treating congenital disorders of glycosylation MAGGIE'S PEARL, LLC (US) 2021-11-02 US disclosed
US-20040214882-A1 Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones INTERHEALTH NUTRACEUTICALS INCORPORATED 2004-10-28 US disclosed
US-20040097493-A1 For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions HOFFMANN-LA ROCHE INC. 2004-05-20 US disclosed
EP-1278417-A1 COMPOSITIONS AND METHODS OF TREATING, REDUCING, AND PREVENTING CARDIOVASCULAR DISEASES AND DISORDERS WITH POLYMETHOXYFLAVONES KGK Synergie (CA) 2003-01-29 EP disclosed
EP-1119353-A4 COMPOSITIONS AND METHODS OF INHIBITING NEOPLASTIC DISEASES WITH COMPOUNDS RELATED TO LIMOCITRIN AND 5-DESMETHYL SINENSETIN KGK SYNERGIZE INC (CA) 2002-08-28 EP disclosed
WO-2001070029-A1 COMPOSITIONS AND METHODS OF TREATING, REDUCING, AND PREVENTING CARDIOVASCULAR DISEASES AND DISORDERS WITH POLYMETHOXYFLAVONES KGK SYNERGIE (CA) 2001-09-27 WO disclosed
EP-1119353-A1 COMPOSITIONS AND METHODS OF INHIBITING NEOPLASTIC DISEASES WITH COMPOUNDS RELATED TO LIMOCITRIN AND 5-DESMETHYL SINENSETIN KGK Synergize Inc. (CA) 2001-08-01 EP disclosed
WO-2000019998-A1 COMPOSITIONS AND METHODS OF INHIBITING NEOPLASTIC DISEASES WITH COMPOUNDS RELATED TO LIMOCITRIN AND 5-DESMETHYL SINENSETIN KGK SYNERGIZE (CA) 2000-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050249803-A1 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols TTPA, CCNE2, PTGES KDM4E 1084/4885CYP3A4 1187/4885MAPT 1749/4885
US-11160794-B2 Methods for treating congenital disorders of glycosylation MAN1B1, MAN2B1, GAA KDM4E 3915/4885CYP3A4 4252/4885MAPT 3244/4885
US-20060003947-A1 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols TTPA, PLA2G10, GSTO1 KDM4E 652/4885CYP3A4 890/4885MAPT 3282/4885
US-20220125766-A1 METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION MAN1B1, MAN2B1, GAA KDM4E 3915/4885CYP3A4 4252/4885MAPT 3244/4885
US-20040097493-A1 For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions FGFR1, MAPK1, FGF1 KDM4E 4627/4885CYP3A4 4702/4885MAPT 1042/4885
US-20040214882-A1 Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones TNNT2, PLIN3, TNNI3 KDM4E 2659/4885CYP3A4 926/4885MAPT 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.